{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:32:13Z","timestamp":1768483933372,"version":"3.49.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00467-020-04867-y","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T09:02:59Z","timestamp":1609664579000},"page":"2659-2673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biomarkers in pediatric glomerulonephritis and nephrotic syndrome"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4164-3251","authenticated-orcid":false,"given":"Gabriel","family":"Cara-Fuentes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Smoyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"4867_CR1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1053\/j.ajkd.2015.12.011","volume":"67","author":"JR Ingelfinger","year":"2016","unstructured":"Ingelfinger JR, Kalantar-Zadeh K, Schaefer F (2016) World kidney day 2016: averting the legacy of kidney disease--focus on childhood. Am J Kidney Dis 67:349\u2013354","journal-title":"Am J Kidney Dis"},{"key":"4867_CR2","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.2215\/CJN.06620615","volume":"10","author":"MN Rheault","year":"2015","unstructured":"Rheault MN, Zhang L, Selewski DT, Kallash M, Tran CL, Seamon M, Katsoufis C, Ashoor I, Hernandez J, Supe-Markovina K, D'Alessandri-Silva C, DeJesus-Gonzalez N, Vasylyeva TL, Formeck C, Woll C, Gbadegesin R, Geier P, Devarajan P, Carpenter SL, Kerlin BA, Smoyer WE, Midwest Pediatric Nephrology Consortium (2015) AKI in children hospitalized with nephrotic syndrome. Clin J Am Soc Nephrol 10:2110\u20132118. https:\/\/doi.org\/10.2215\/CJN.06620615","journal-title":"Clin J Am Soc Nephrol"},{"key":"4867_CR3","doi-asserted-by":"publisher","first-page":"e012143","DOI":"10.1161\/JAHA.119.012143","volume":"8","author":"IF Ashoor","year":"2019","unstructured":"Ashoor IF, Mansfield SA, O'Shaughnessy MM, Parekh RS, Zee J, Vasylyeva TL, Kogon AJ, Sethna CB, Glenn DA, Chishti AS, Weaver DJ, Helmuth ME, Fernandez HE, Rheault MN, CureGN Consortium (2019) Prevalence of cardiovascular disease risk factors in childhood glomerular diseases. J Am Heart Assoc 8:e012143. https:\/\/doi.org\/10.1161\/JAHA.119.012143","journal-title":"J Am Heart Assoc"},{"key":"4867_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli M, Massella L, Ruggiero B, Emma F (2017) Minimal change disease. Clin J Am Soc Nephrol 12:332\u2013345. https:\/\/doi.org\/10.2215\/CJN.05000516","journal-title":"Clin J Am Soc Nephrol"},{"key":"4867_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa0810457","journal-title":"N Engl J Med"},{"key":"4867_CR6","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.2215\/CJN.07210810","volume":"6","author":"JM Hofstra","year":"2011","unstructured":"Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ (2011) Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6:1286\u20131291. https:\/\/doi.org\/10.2215\/CJN.07210810","journal-title":"Clin J Am Soc Nephrol"},{"key":"4867_CR7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1111\/j.1600-6143.2011.03957.x","volume":"12","author":"CD Blosser","year":"2012","unstructured":"Blosser CD, Ayalon R, Nair R, Thomas C, Beck LH Jr (2012) Very early recurrence of anti-phospholipase A2 receptor-positive membranous nephropathy after transplantation. Am J Transplant 12:1637\u20131642. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03957.x","journal-title":"Am J Transplant"},{"key":"4867_CR8","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","volume":"22","author":"LH Beck Jr","year":"2011","unstructured":"Beck LH Jr, Fervenza FC, Beck DM, Bonegio RGB, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ (2011) Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22:1543\u20131550. https:\/\/doi.org\/10.1681\/ASN.2010111125","journal-title":"J Am Soc Nephrol"},{"key":"4867_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","unstructured":"Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89\u201395. https:\/\/doi.org\/10.1067\/mcp.2001.113989","journal-title":"Clin Pharmacol Ther"},{"key":"4867_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1602\/neurorx.1.2.182","volume":"1","author":"R Mayeux","year":"2004","unstructured":"Mayeux R (2004) Biomarkers: potential uses and limitations. NeuroRx 1:182\u2013188. https:\/\/doi.org\/10.1602\/neurorx.1.2.182","journal-title":"NeuroRx"},{"key":"4867_CR11","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2217\/bmm.14.92","volume":"8","author":"VJ Hwang","year":"2014","unstructured":"Hwang VJ, Ulu A, van Hoorebeke J, Weiss RH (2014) Biomarkers in IgA nephropathy. Biomark Med 8:1263\u20131277. https:\/\/doi.org\/10.2217\/bmm.14.92","journal-title":"Biomark Med"},{"key":"4867_CR12","first-page":"271","volume":"44","author":"JL Olson","year":"1981","unstructured":"Olson JL, Rennke HG, Venkatachalam MA (1981) Alterations in the charge and size selectivity barrier of the glomerular filter in aminonucleoside nephrosis in rats. Lab Investig 44:271\u2013279","journal-title":"Lab Investig"},{"key":"4867_CR13","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1172\/JCI20402","volume":"113","author":"J Reiser","year":"2004","unstructured":"Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P (2004) Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 113:1390\u20131397. https:\/\/doi.org\/10.1172\/JCI20402","journal-title":"J Clin Invest"},{"key":"4867_CR14","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1046\/j.1523-1755.2001.060003957.x","volume":"60","author":"YH Kim","year":"2001","unstructured":"Kim YH, Goyal M, Kurnit D, Wharram B, Wiggins J, Holzman L, Kershaw D, Wiggins R (2001) Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 60:957\u2013968. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.060003957.x","journal-title":"Kidney Int"},{"key":"4867_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1084\/jem.166.1.109","volume":"166","author":"D Kerjaschki","year":"1987","unstructured":"Kerjaschki D, Miettinen A, Farquhar MG (1987) Initial events in the formation of immune deposits in passive Heymann nephritis. gp330-anti-gp330 immune complexes form in epithelial coated pits and rapidly become attached to the glomerular basement membrane. J Exp Med 166:109\u2013128. https:\/\/doi.org\/10.1084\/jem.166.1.109","journal-title":"J Exp Med"},{"key":"4867_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"JC Rodrigues","year":"2017","unstructured":"Rodrigues JC, Haas M, Reich HN (2017) IgA nephropathy. Clin J Am Soc Nephrol 12:677\u2013686. https:\/\/doi.org\/10.2215\/CJN.07420716","journal-title":"Clin J Am Soc Nephrol"},{"key":"4867_CR17","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1172\/JCI38468","volume":"119","author":"H Suzuki","year":"2009","unstructured":"Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J (2009) Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119:1668\u20131677. https:\/\/doi.org\/10.1172\/JCI38468","journal-title":"J Clin Invest"},{"key":"4867_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.semnephrol.2004.01.001","volume":"24","author":"G D'Amico","year":"2004","unstructured":"D'Amico G (2004) Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24:179\u2013196. https:\/\/doi.org\/10.1016\/j.semnephrol.2004.01.001","journal-title":"Semin Nephrol"},{"key":"4867_CR19","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00467-017-3610-y","volume":"32","author":"RCG Fabiano","year":"2017","unstructured":"Fabiano RCG, de Almeida Ara\u00fajo S, Bambirra EA, Oliveira EA, Sim\u00f5es E, Silva AC, Pinheiro SVB (2017) Mesangial C4d deposition may predict progression of kidney disease in pediatric patients with IgA nephropathy. Pediatr Nephrol 32:1211\u20131220. https:\/\/doi.org\/10.1007\/s00467-017-3610-y","journal-title":"Pediatr Nephrol"},{"key":"4867_CR20","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/sj.ki.5002185","volume":"71","author":"Z Moldoveanu","year":"2007","unstructured":"Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, Huang WQ, Anreddy SR, Hall S, Hastings MC, Lau KK, Cook WJ, Novak J (2007) Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71:1148\u20131154. https:\/\/doi.org\/10.1038\/sj.ki.5002185","journal-title":"Kidney Int"},{"key":"4867_CR21","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1681\/ASN.2012010053","volume":"23","author":"F Berthoux","year":"2012","unstructured":"Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J (2012) Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23:1579\u20131587. https:\/\/doi.org\/10.1681\/ASN.2012010053","journal-title":"J Am Soc Nephrol"},{"key":"4867_CR22","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/ndt\/16.7.1364","volume":"16","author":"EM Briganti","year":"2001","unstructured":"Briganti EM, Dowling J, Finlay M, Hill PA, Jones CL, Kincaid-Smith PS, Sinclair R, McNeil JJ, Atkins RC (2001) The incidence of biopsy-proven glomerulonephritis in Australia. Nephrol Dial Transplant 16:1364\u20131367. https:\/\/doi.org\/10.1093\/ndt\/16.7.1364","journal-title":"Nephrol Dial Transplant"},{"key":"4867_CR23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMra1108178","volume":"366","author":"S Sethi","year":"2012","unstructured":"Sethi S, Fervenza FC (2012) Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med 366:1119\u20131131. https:\/\/doi.org\/10.1056\/NEJMra1108178","journal-title":"N Engl J Med"},{"key":"4867_CR24","doi-asserted-by":"crossref","unstructured":"Fakhouri F, Fr\u00e9meaux-Bacchi V, No\u00ebl LH, Cook HT, Pickering MC (2010) C3 glomerulopathy: a new classification. Nat Rev Nephrol 6:494\u2013499","DOI":"10.1038\/nrneph.2010.85"},{"key":"4867_CR25","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"82","author":"A Servais","year":"2012","unstructured":"Servais A, No\u00ebl LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Gr\u00fcnfeld JP, Niaudet P, Lesavre P, Fr\u00e9meaux-Bacchi V (2012) Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82:454\u2013464. https:\/\/doi.org\/10.1038\/ki.2012.63","journal-title":"Kidney Int"},{"key":"4867_CR26","first-page":"253","volume":"54","author":"AT Gewurz","year":"1983","unstructured":"Gewurz AT, Imherr SM, Strauss S, Gewurz H, Mold C (1983) C3 nephritic factor and hypocomplementaemia in a clinically healthy individual. Clin Exp Immunol 54:253\u2013258","journal-title":"Clin Exp Immunol"},{"key":"4867_CR27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","volume":"12","author":"WG Couser","year":"2017","unstructured":"Couser WG (2017) Primary membranous nephropathy. Clin J Am Soc Nephrol 12:983\u2013997. https:\/\/doi.org\/10.2215\/CJN.11761116","journal-title":"Clin J Am Soc Nephrol"},{"key":"4867_CR28","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00467-009-1324-5","volume":"25","author":"S Menon","year":"2010","unstructured":"Menon S, Valentini RP (2010) Membranous nephropathy in children: clinical presentation and therapeutic approach. Pediatr Nephrol 25:1419\u20131428. https:\/\/doi.org\/10.1007\/s00467-009-1324-5","journal-title":"Pediatr Nephrol"},{"key":"4867_CR29","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","volume":"66","author":"S Troyanov","year":"2004","unstructured":"Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC (2004) Toronto glomerulonephritis registry group. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 66:1199\u20131205. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00873.x","journal-title":"Kidney Int"},{"key":"4867_CR30","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1009742","volume":"364","author":"HC Stanescu","year":"2011","unstructured":"Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, Voinescu C, Patel N, Pearce K, Hubank M, Stephens HA, Laundy V, Padmanabhan S, Zawadzka A, Hofstra JM, Coenen MJ, den Heijer M, Kiemeney LA, Bacq-Daian D, Stengel B, Powis SH, Brenchley P, Feehally J, Rees AJ, Debiec H, Wetzels JF, Ronco P, Mathieson PW, Kleta R (2011) Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 364:616\u2013626. https:\/\/doi.org\/10.1056\/NEJMoa1009742","journal-title":"N Engl J Med"},{"key":"4867_CR31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/ctr.12711","volume":"30","author":"G Gupta","year":"2016","unstructured":"Gupta G, Fattah H, Ayalon R, Kidd J, Gehr T, Quintana LF, Kimball P, Sadruddin S, Massey HD, Kumar D, King AL, Beck LH Jr (2016) Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation. Clin Transpl 30:461\u2013469. https:\/\/doi.org\/10.1111\/ctr.12711","journal-title":"Clin Transpl"},{"key":"4867_CR32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMc1011678","volume":"364","author":"H Debiec","year":"2011","unstructured":"Debiec H, Ronco P (2011) PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 364:689\u2013690. https:\/\/doi.org\/10.1056\/NEJMc1011678","journal-title":"N Engl J Med"},{"key":"4867_CR33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/modpathol.2012.207","volume":"26","author":"CP Larsen","year":"2013","unstructured":"Larsen CP, Messias NC, Silva FG, Messias E, Walker PD (2013) Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 26:709\u2013715. https:\/\/doi.org\/10.1038\/modpathol.2012.207","journal-title":"Mod Pathol"},{"key":"4867_CR34","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1681\/ASN.2010090967","volume":"22","author":"W Qin","year":"2011","unstructured":"Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z (2011) Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 22:1137\u20131143. https:\/\/doi.org\/10.1681\/ASN.2010090967","journal-title":"J Am Soc Nephrol"},{"key":"4867_CR35","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/ndt\/gfr247","volume":"26","author":"E Hoxha","year":"2011","unstructured":"Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, Helmchen U, Stahl RA (2011) An immunofluorescence test for phospholipase-a2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 26:2526\u20132532. https:\/\/doi.org\/10.1093\/ndt\/gfr247","journal-title":"Nephrol Dial Transplant"},{"key":"4867_CR36","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","volume":"371","author":"NM Tomas","year":"2014","unstructured":"Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RAK, Lambeau G (2014) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371:2277\u20132287. https:\/\/doi.org\/10.1056\/NEJMoa1409354","journal-title":"N Engl J Med"},{"key":"4867_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(18)30536-1","journal-title":"Lancet"},{"key":"4867_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nm.2261","volume":"17","author":"LC Clement","year":"2011","unstructured":"Clement LC, Avila-Casado C, Mac\u00e9 C, Soria E, Bakker WW, Kersten S, Chugh SS (2011) Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 17:117\u2013122. https:\/\/doi.org\/10.1038\/nm.2261","journal-title":"Nat Med"},{"key":"4867_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nm.3396","volume":"20","author":"LC Clement","year":"2014","unstructured":"Clement LC, Mac\u00e9 C, Avila-Casado C, Joles JA, Kersten S, Chugh SS (2014) Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med 20:37\u201346. https:\/\/doi.org\/10.1038\/nm.3396","journal-title":"Nat Med"},{"key":"4867_CR40","doi-asserted-by":"publisher","first-page":"e0137049","DOI":"10.1371\/journal.pone.0137049","volume":"10","author":"JS Li","year":"2015","unstructured":"Li JS, Chen X, Peng L, Wei SY, Zhao SL, Diao TT, He YX, Liu F, Wei QJ, Zhang QF, Li B (2015) Angiopoietin-like-4, a potential target of tacrolimus, predicts earlier podocyte injury in minimal change disease. PLoS One 10:e0137049. https:\/\/doi.org\/10.1371\/journal.pone.0137049","journal-title":"PLoS One"},{"key":"4867_CR41","doi-asserted-by":"publisher","first-page":"e0176198","DOI":"10.1371\/journal.pone.0176198","volume":"12","author":"G Cara-Fuentes","year":"2017","unstructured":"Cara-Fuentes G, Segarra A, Silva-Sanchez C, Wang H, Lanaspa MA, Johnson RJ, Garin EH (2017) Angiopoietin-like-4 and minimal change disease. PLoS One 12:e0176198. https:\/\/doi.org\/10.1371\/journal.pone.0176198","journal-title":"PLoS One"},{"key":"4867_CR42","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1681\/ASN.2012020133","volume":"24","author":"A Goldwich","year":"2013","unstructured":"Goldwich A, Burkard M, Olke M, Daniel C, Amann K, Hugo C, Kurts C, Steinkasserer A, Gessner A (2013) Podocytes are nonhematopoietic professional antigen-presenting cells. J Am Soc Nephrol 24:906\u2013916. https:\/\/doi.org\/10.1681\/ASN.2012020133","journal-title":"J Am Soc Nephrol"},{"key":"4867_CR43","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1242\/dmm.023440","volume":"9","author":"N Jain","year":"2016","unstructured":"Jain N, Khullar B, Oswal N, Banoth B, Joshi P, Ravindran B, Panda S, Basak S, George A, Rath S, Bal V, Sopory S (2016) TLR-mediated albuminuria needs TNF\u03b1-mediated cooperativity between TLRs present in hematopoietic tissues and CD80 present on non-hematopoietic tissues in mice. Dis Model Mech 9:707\u2013717. https:\/\/doi.org\/10.1242\/dmm.023440","journal-title":"Dis Model Mech"},{"key":"4867_CR44","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s10157-017-1489-3","volume":"22","author":"B Khullar","year":"2018","unstructured":"Khullar B, Balyan R, Oswal N, Jain N, Sharma A, Abdin MZ, Bagga A, Bhatnagar S, Wadhwa N, Natchu UCM, George A, Rath S, Bal V, Sopory S (2018) Interaction of CD80 with Neph1: a potential mechanism of podocyte injury. Clin Exp Nephrol 22:508\u2013516. https:\/\/doi.org\/10.1007\/s10157-017-1489-3","journal-title":"Clin Exp Nephrol"},{"key":"4867_CR45","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","volume":"369","author":"CC Yu","year":"2013","unstructured":"Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW 3rd, Mundel P (2013) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369:2416\u20132423. https:\/\/doi.org\/10.1056\/NEJMoa1304572","journal-title":"N Engl J Med"},{"key":"4867_CR46","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1681\/ASN.2007080836","volume":"20","author":"EH Garin","year":"2009","unstructured":"Garin EH, Diaz LN, Mu W, Wasserfall C, Araya C, Segal M, Johnson RJ (2009) Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 20:260\u2013266. https:\/\/doi.org\/10.1681\/ASN.2007080836","journal-title":"J Am Soc Nephrol"},{"key":"4867_CR47","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/ki.2010.143","volume":"78","author":"EH Garin","year":"2010","unstructured":"Garin EH, Mu W, Arthur JM, Rivard CJ, Araya CE, Shimada M, Johnson RJ (2010) Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 78:296\u2013302. https:\/\/doi.org\/10.1038\/ki.2010.143","journal-title":"Kidney Int"},{"key":"4867_CR48","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s00467-014-2874-8","volume":"29","author":"G Cara-Fuentes","year":"2014","unstructured":"Cara-Fuentes G, Wasserfall CH, Wang H, Johnson RJ, Garin EH (2014) Minimal change disease: a dysregulation of the podocyte CD80-CTLA-4 axis? Pediatr Nephrol 29:2333\u20132340. https:\/\/doi.org\/10.1007\/s00467-014-2874-8","journal-title":"Pediatr Nephrol"},{"key":"4867_CR49","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00467-013-2679-1","volume":"29","author":"G Cara-Fuentes","year":"2014","unstructured":"Cara-Fuentes G, Wei C, Segarra A, Ishimoto T, Rivard C, Johnson RJ, Reiser J, Garin EH (2014) CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance. Pediatr Nephrol 29:1363\u20131371. https:\/\/doi.org\/10.1007\/s00467-013-2679-1","journal-title":"Pediatr Nephrol"},{"key":"4867_CR50","doi-asserted-by":"publisher","first-page":"17322","DOI":"10.1038\/s41598-018-35798-2","volume":"8","author":"S Minamikawa","year":"2018","unstructured":"Minamikawa S, Nozu K, Maeta S, Yamamura T, Nakanishi K, Fujimura J, Horinouchi T, Nagano C, Sakakibara N, Nagase H, Shima H, Noda K, Ninchoji T, Kaito H, Iijima K (2018) The utility of urinary CD80 as a diagnostic marker in patients with renal diseases. Sci Rep 8:17322. https:\/\/doi.org\/10.1038\/s41598-018-35798-2","journal-title":"Sci Rep"},{"key":"4867_CR51","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00467-017-3613-8","volume":"32","author":"OP Mishra","year":"2017","unstructured":"Mishra OP, Kumar R, Narayan G, Srivastava P, Abhinay A, Prasad R, Singh A, Batra VV (2017) Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome. Pediatr Nephrol 32:1355\u20131361. https:\/\/doi.org\/10.1007\/s00467-017-3613-8","journal-title":"Pediatr Nephrol"},{"key":"4867_CR52","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00467-014-2915-3","volume":"30","author":"C Ling","year":"2015","unstructured":"Ling C, Liu X, Shen Y, Chen Z, Fan J, Jiang Y, Meng Q (2015) Urinary CD80 levels as a diagnostic biomarker of minimal change disease. Pediatr Nephrol 30:309\u2013316. https:\/\/doi.org\/10.1007\/s00467-014-2915-3","journal-title":"Pediatr Nephrol"},{"key":"4867_CR53","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41390-018-0088-7","volume":"84","author":"D Bhatia","year":"2018","unstructured":"Bhatia D, Sinha A, Hari P, Sopory S, Saini S, Puraswani M, Saini H, Mitra DK, Bagga A (2018) Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome. Pediatr Res 84:520\u2013526. https:\/\/doi.org\/10.1038\/s41390-018-0088-7","journal-title":"Pediatr Res"},{"key":"4867_CR54","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.ekir.2020.08.001","volume":"5","author":"AM Gonzalez Guerrico","year":"2020","unstructured":"Gonzalez Guerrico AM, Lieske J, Klee G, Kumar S, Lopez-Baez V, Wright AM, Bobart S, Shevell D, Maldonado M, Troost JP, Hogan MC, Nephrotic Syndrome Study Network Consortium (NEPTUNE) (2020) Urinary CD80 discriminates among glomerular disease types and reflects disease activity. Kidney Int Rep 5:2021\u20132031. https:\/\/doi.org\/10.1016\/j.ekir.2020.08.001","journal-title":"Kidney Int Rep"},{"key":"4867_CR55","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00467-018-3885-7","volume":"33","author":"C Ling","year":"2018","unstructured":"Ling C, Liu X, Shen Y, Chen Z, Fan J, Jiang Y, Meng Q (2018) Urinary CD80 excretion is a predictor of good outcome in children with primary nephrotic syndrome. Pediatr Nephrol 33:1183\u20131187. https:\/\/doi.org\/10.1007\/s00467-018-3885-7","journal-title":"Pediatr Nephrol"},{"key":"4867_CR56","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.ekir.2019.05.1155","volume":"4","author":"R Isom","year":"2019","unstructured":"Isom R, Shoor S, Higgins J, Cara-Fuentes G, Johnson RJ (2019) Abatacept in steroid-dependent minimal change disease and CD80-uria. Kidney Int Rep 4:1349\u20131353. https:\/\/doi.org\/10.1016\/j.ekir.2019.05.1155","journal-title":"Kidney Int Rep"},{"key":"4867_CR57","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00467-014-2957-6","volume":"30","author":"EH Garin","year":"2015","unstructured":"Garin EH, Reiser J, Cara-Fuentes G, Wei C, Matar D, Wang H, Alachkar N, Johnson RJ (2015) Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatr Nephrol 30:469\u2013477. https:\/\/doi.org\/10.1007\/s00467-014-2957-6","journal-title":"Pediatr Nephrol"},{"key":"4867_CR58","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1053\/j.ajkd.2014.07.023","volume":"64","author":"CP Larsen","year":"2014","unstructured":"Larsen CP, Messias NC, Walker PD (2014) B7-1 immunostaining in proteinuric kidney disease. Am J Kidney Dis 64:1001\u20131003. https:\/\/doi.org\/10.1053\/j.ajkd.2014.07.023","journal-title":"Am J Kidney Dis"},{"key":"4867_CR59","doi-asserted-by":"publisher","first-page":"F335","DOI":"10.1152\/ajprenal.00510.2015","volume":"310","author":"R Novelli","year":"2016","unstructured":"Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G (2016) Any value of podocyte B7-1 as a biomarker in human MCD and FSGS? Am J Physiol Renal Physiol 310:F335\u2013F341. https:\/\/doi.org\/10.1152\/ajprenal.00510.2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"4867_CR60","doi-asserted-by":"publisher","first-page":"41859","DOI":"10.1038\/srep41859","volume":"7","author":"SW Lee","year":"2017","unstructured":"Lee SW, Baek SH, Paik JH, Kim S, Na KY, Chae DW, Chin H (2017) Tubular B7-1 expression parallels proteinuria levels, but not clinical outcomes in adult minimal change disease patients. Sci Rep 7:41859. https:\/\/doi.org\/10.1038\/srep41859","journal-title":"Sci Rep"},{"key":"4867_CR61","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s00467-020-04541-3","volume":"35","author":"G Cara-Fuentes","year":"2020","unstructured":"Cara-Fuentes G, Venkatareddy M, Verma R, Segarra A, Cleuren AC, Mart\u00ednez-Ramos A, Johnson RJ, Garg P (2020) Glomerular endothelial cells and podocytes can express CD80 in patients with minimal change disease during relapse. Pediatr Nephrol 35:1887\u20131896. https:\/\/doi.org\/10.1007\/s00467-020-04541-3","journal-title":"Pediatr Nephrol"},{"key":"4867_CR62","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1681\/ASN.2015091002","volume":"27","author":"M Delville","year":"2016","unstructured":"Delville M, Baye E, Durrbach A, Audard V, Kofman T, Braun L, Olagne J, Nguyen C, Desch\u00eanes G, Moulin B, Delahousse M, Kesler-Roussey G, Beaudreuil S, Martinez F, Rabant M, Grimbert P, Gallazzini M, Terzi F, Legendre C, Canaud G (2016) B7-1 blockade does not improve post-transplant nephrotic syndrome caused by recurrent FSGS. J Am Soc Nephrol 27:2520\u20132527. https:\/\/doi.org\/10.1681\/ASN.2015091002","journal-title":"J Am Soc Nephrol"},{"key":"4867_CR63","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1681\/ASN.V1351238","volume":"13","author":"D Sahali","year":"2002","unstructured":"Sahali D, Pawlak A, Valanciut\u00e9 A, Grimbert P, Lang P, Remy P, Bensman A, Guella\u00ebn G (2002) A novel approach to investigation of the pathogenesis of active minimal-change nephrotic syndrome using subtracted cDNA library screening. J Am Soc Nephrol 13:1238\u20131247","journal-title":"J Am Soc Nephrol"},{"key":"4867_CR64","doi-asserted-by":"publisher","first-page":"ra39","DOI":"10.1126\/scisignal.2000678","volume":"3","author":"SY Zhang","year":"2010","unstructured":"Zhang SY, Kamal M, Dahan K, Pawlak A, Ory V, Desvaux D, Audard V, Candelier M, BenMohamed F, Matignon M, Christov C, Decrouy X, Bernard V, Mangiapan G, Lang P, Guella\u00ebn G, Ronco P, Sahali D (2010) c-mip impairs podocyte proximal signaling and induces heavy proteinuria. [published correction appears in]. Sci Signal 3:ra39. https:\/\/doi.org\/10.1126\/scisignal.2000678","journal-title":"Sci Signal"},{"key":"4867_CR65","doi-asserted-by":"publisher","first-page":"e0207066","DOI":"10.1371\/journal.pone.0207066","volume":"13","author":"K Bouachi","year":"2018","unstructured":"Bouachi K, Moktefi A, Zhang SY, Oniszczuk J, Sendeyo K, Remy P, Audard V, Pawlak A, Ollero M, Sahali D (2018) Expression of CMIP in podocytes is restricted to specific classes of lupus nephritis. PLoS One 13:e0207066. https:\/\/doi.org\/10.1371\/journal.pone.0207066","journal-title":"PLoS One"},{"key":"4867_CR66","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.2215\/CJN.03800609","volume":"5","author":"ET McCarthy","year":"2010","unstructured":"McCarthy ET, Sharma M, Savin VJ (2010) Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5:2115\u20132121. https:\/\/doi.org\/10.2215\/CJN.03800609","journal-title":"Clin J Am Soc Nephrol"},{"key":"4867_CR67","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.trsl.2015.03.002","volume":"166","author":"M Sharma","year":"2015","unstructured":"Sharma M, Zhou J, Gauchat JF, Sharma R, McCarthy ET, Srivastava T, Savin VJ (2015) Janus kinase 2\/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. Transl Res 166:384\u2013398. https:\/\/doi.org\/10.1016\/j.trsl.2015.03.002","journal-title":"Transl Res"},{"key":"4867_CR68","doi-asserted-by":"publisher","first-page":"714964","DOI":"10.1155\/2015\/714964","volume":"2015","author":"VJ Savin","year":"2015","unstructured":"Savin VJ, Sharma M, Zhou J, Gennochi D, Fields T, Sharma R, McCarthy ET, Srivastava T, Domen J, Tormo A, Gauchat JF (2015) Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family. J Immunol Res 2015:714964. https:\/\/doi.org\/10.1155\/2015\/714964","journal-title":"J Immunol Res"},{"key":"4867_CR69","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.trsl.2008.04.001","volume":"151","author":"VJ Savin","year":"2008","unstructured":"Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M (2008) Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 151:288\u2013292. https:\/\/doi.org\/10.1016\/j.trsl.2008.04.001","journal-title":"Transl Res"},{"key":"4867_CR70","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s00467-013-2539-z","volume":"28","author":"K Sgambat","year":"2013","unstructured":"Sgambat K, Banks M, Moudgil A (2013) Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome. Pediatr Nephrol 28:2131\u20132135. https:\/\/doi.org\/10.1007\/s00467-013-2539-z","journal-title":"Pediatr Nephrol"},{"key":"4867_CR71","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nm1696","volume":"14","author":"C Wei","year":"2008","unstructured":"Wei C, M\u00f6ller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J (2008) Modification of kidney barrier function by the urokinase receptor. Nat Med 14:55\u201363. https:\/\/doi.org\/10.1038\/nm1696","journal-title":"Nat Med"},{"key":"4867_CR72","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nm.2411","volume":"17","author":"C Wei","year":"2011","unstructured":"Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17:952\u2013960. https:\/\/doi.org\/10.1038\/nm.2411","journal-title":"Nat Med"},{"key":"4867_CR73","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1172\/JCI124793","volume":"129","author":"C Wei","year":"2019","unstructured":"Wei C, Li J, Adair BD, Zhu K, Cai J, Merchant M, Samelko B, Liao Z, Koh KH, Tardi NJ, Dande RR, Liu S, Ma J, Dibartolo S, H\u00e4gele S, Peev V, Hayek SS, Cimbaluk DJ, Tracy M, Klein J, Sever S, Shattil SJ, Arnaout MA, Reiser J (2019) uPAR isoform 2 forms a dimer and induces severe kidney disease in mice. J Clin Invest 129:1946\u20131959. https:\/\/doi.org\/10.1172\/JCI124793","journal-title":"J Clin Invest"},{"key":"4867_CR74","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/ki.2013.505","volume":"85","author":"B Meijers","year":"2014","unstructured":"Meijers B, Maas RJ, Sprangers B, Claes K, Poesen R, Bammens B, Naesens M, Deegens JKJ, Dietrich R, Storr M, Wetzels JFM, Evenepoel P, Kuypers D (2014) The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 85:636\u2013640. https:\/\/doi.org\/10.1038\/ki.2013.505","journal-title":"Kidney Int"},{"key":"4867_CR75","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/ki.2013.546","volume":"85","author":"A Sinha","year":"2014","unstructured":"Sinha A, Bajpai J, Saini S, Bhatia D, Gupta A, Puraswani M, Dinda AK, Agarwal SK, Sopory S, Pandey RM, Hari P, Bagga A (2014) Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int 85:649\u2013658. https:\/\/doi.org\/10.1038\/ki.2013.546","journal-title":"Kidney Int"},{"key":"4867_CR76","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cjca.2015.03.023","volume":"31","author":"GW Hodges","year":"2015","unstructured":"Hodges GW, Bang CN, Wachtell K, Eugen-Olsen J, Jeppesen JL (2015) suPAR: a new biomarker for cardiovascular disease? Can J Cardiol 31:1293\u20131302. https:\/\/doi.org\/10.1016\/j.cjca.2015.03.023","journal-title":"Can J Cardiol"},{"key":"4867_CR77","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/ki.2013.549","volume":"85","author":"D Schl\u00f6ndorff","year":"2014","unstructured":"Schl\u00f6ndorff D (2014) Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS? Kidney Int 85:499\u2013501. https:\/\/doi.org\/10.1038\/ki.2013.549","journal-title":"Kidney Int"},{"key":"4867_CR78","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/TP.0000000000002930","volume":"104","author":"E Harel","year":"2020","unstructured":"Harel E, Shoji J, Abraham V, Miller L, Laszik ZG, King A, Dobi D, Szabo G, Hann B, Sarwal MM, Craik CS, Vincenti F (2020) Further evidence that the soluble urokinase plasminogen activator receptor does not directly injure mice or human Podocytes. Transplantation 104:54\u201360. https:\/\/doi.org\/10.1097\/TP.0000000000002930","journal-title":"Transplantation"},{"key":"4867_CR79","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1681\/ASN.2013040425","volume":"25","author":"D Cathelin","year":"2014","unstructured":"Cathelin D, Placier S, Ploug M, Verpont MC, Vandermeersch S, Luque Y, Hertig A, Rondeau E, Mesnard L (2014) Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. J Am Soc Nephrol 25:1662\u20131668. https:\/\/doi.org\/10.1681\/ASN.2013040425","journal-title":"J Am Soc Nephrol"},{"key":"4867_CR80","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1681\/ASN.V1081700","volume":"10","author":"PK Cheung","year":"1999","unstructured":"Cheung PK, Stulp B, Immenschuh S, Borghuis T, Baller JF, Bakker WW (1999) Is 100KF an isoform of hemopexin? Immunochemical characterization of the vasoactive plasma factor 100KF. J Am Soc Nephrol 10:1700\u20131708","journal-title":"J Am Soc Nephrol"},{"key":"4867_CR81","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1046\/j.1523-1755.2000.00996.x","volume":"57","author":"PK Cheung","year":"2000","unstructured":"Cheung PK, Klok PA, Baller JF, Bakker WW (2000) Induction of experimental proteinuria in vivo following infusion of human plasma hemopexin. Kidney Int 57:1512\u20131520. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00996.x","journal-title":"Kidney Int"},{"key":"4867_CR82","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1007\/s00467-005-1936-3","volume":"20","author":"WW Bakker","year":"2005","unstructured":"Bakker WW, van Dael CML, Pierik LJWM, van Wijk JAE, Nauta J, Borghuis T, Kapojos JJ (2005) Altered activity of plasma hemopexin in patients with minimal change disease in relapse. Pediatr Nephrol 20:1410\u20131415. https:\/\/doi.org\/10.1007\/s00467-005-1936-3","journal-title":"Pediatr Nephrol"},{"key":"4867_CR83","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1681\/ASN.2007080940","volume":"19","author":"R Lennon","year":"2008","unstructured":"Lennon R, Singh A, Welsh GI, Coward RJ, Satchell S, Ni L, Mathieson PW, Bakker WW, Saleem MA (2008) Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes. J Am Soc Nephrol 19:2140\u20132149. https:\/\/doi.org\/10.1681\/ASN.2007080940","journal-title":"J Am Soc Nephrol"},{"key":"4867_CR84","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.cgh.2012.08.012","volume":"10","author":"A Fasano","year":"2012","unstructured":"Fasano A (2012) Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications. Clin Gastroenterol Hepatol 10:1096\u20131100. https:\/\/doi.org\/10.1016\/j.cgh.2012.08.012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4867_CR85","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fped.2019.00197","volume":"7","author":"H Trachtman","year":"2019","unstructured":"Trachtman H, Gipson DS, Lemley KV, Troost JP, Faul C, Morrison DJ, Vento SM, Ahn DH, Goldberg JD (2019) Plasma zonulin levels in childhood nephrotic syndrome. Front Pediatr 7:197. https:\/\/doi.org\/10.3389\/fped.2019.00197","journal-title":"Front Pediatr"},{"key":"4867_CR86","doi-asserted-by":"publisher","first-page":"e0210728","DOI":"10.1371\/journal.pone.0210728","volume":"14","author":"M Ajamian","year":"2019","unstructured":"Ajamian M, Steer D, Rosella G, Gibson PR (2019) Serum zonulin as a marker of intestinal mucosal barrier function: may not be what it seems. PLoS One 14:e0210728. https:\/\/doi.org\/10.1371\/journal.pone.0210728","journal-title":"PLoS One"},{"key":"4867_CR87","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00467-004-1694-7","volume":"20","author":"FL Weng","year":"2005","unstructured":"Weng FL, Shults J, Herskovitz RM, Zemel BS, Leonard MB (2005) Vitamin D insufficiency in steroid-sensitive nephrotic syndrome in remission. Pediatr Nephrol 20:56\u201363. https:\/\/doi.org\/10.1007\/s00467-004-1694-7","journal-title":"Pediatr Nephrol"},{"key":"4867_CR88","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s0140-6736(77)92498-9","volume":"2","author":"JM Barragry","year":"1977","unstructured":"Barragry JM, France MW, Carter ND, Auton JA, Beer M, Boucher BJ, Cohen RD (1977) Vitamin-D metabolism in nephrotic syndrome. Lancet 2:629\u2013632. https:\/\/doi.org\/10.1016\/s0140-6736(77)92498-9","journal-title":"Lancet"},{"key":"4867_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4137\/BMI.S31633","volume":"11","author":"MR Bennett","year":"2016","unstructured":"Bennett MR, Pordal A, Haffner C, Pleasant L, Ma Q, Devarajan P (2016) Urinary vitamin D-binding protein as a biomarker of steroid-resistant nephrotic syndrome. Biomark Insights 11:1\u20136. https:\/\/doi.org\/10.4137\/BMI.S31633","journal-title":"Biomark Insights"},{"key":"4867_CR90","doi-asserted-by":"publisher","first-page":"117727191769583","DOI":"10.1177\/1177271917695832","volume":"12","author":"MR Bennett","year":"2017","unstructured":"Bennett MR, Pleasant L, Haffner C, Ma Q, Haffey WD, Ying J, Wagner M, Greis KD, Devarajan P (2017) A novel biomarker panel to identify steroid resistance in childhood idiopathic nephrotic syndrome. Biomark Insights 12:1177271917695832. https:\/\/doi.org\/10.1177\/1177271917695832","journal-title":"Biomark Insights"},{"key":"4867_CR91","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10157-015-1162-7","volume":"20","author":"CP Suresh","year":"2016","unstructured":"Suresh CP, Saha A, Kaur M, Kumar R, Dubey NK, Basak T, Tanwar VS, Bhardwaj G, Sengupta S, Batra VV, Upadhyay AD (2016) Differentially expressed urinary biomarkers in children with idiopathic nephrotic syndrome. Clin Exp Nephrol 20:273\u2013283. https:\/\/doi.org\/10.1007\/s10157-015-1162-7","journal-title":"Clin Exp Nephrol"},{"key":"4867_CR92","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12882-017-0452-6","volume":"18","author":"V P\u00e9rez","year":"2017","unstructured":"P\u00e9rez V, L\u00f3pez D, Boixadera E, Ibern\u00f3n M, Espinal A, Bonet J, Romero R (2017) Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis. BMC Nephrol 18:49. https:\/\/doi.org\/10.1186\/s12882-017-0452-6","journal-title":"BMC Nephrol"},{"key":"4867_CR93","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2019.09.009","volume":"5","author":"S Agrawal","year":"2019","unstructured":"Agrawal S, Merchant ML, Kino J, Li M, Wilkey DW, Gaweda AE, Brier ME, Chanley MA, Gooding JR, Sumner SJ, Klein JB, Smoyer WE, Midwest Pediatric Nephrology Consortium (2019) Predicting and defining steroid resistance in pediatric nephrotic syndrome using plasma proteomics. Kidney Int Rep 5:66\u201380. https:\/\/doi.org\/10.1016\/j.ekir.2019.09.009","journal-title":"Kidney Int Rep"},{"key":"4867_CR94","doi-asserted-by":"publisher","first-page":"e78531","DOI":"10.1371\/journal.pone.0078531","volume":"8","author":"X Hao","year":"2013","unstructured":"Hao X, Liu X, Wang W, Ren H, Xie J, Shen P, Lin D, Chen N (2013) Distinct metabolic profile of primary focal segmental glomerulosclerosis revealed by NMR-based metabolomics. PLoS One 8:e78531. https:\/\/doi.org\/10.1371\/journal.pone.0078531","journal-title":"PLoS One"},{"key":"4867_CR95","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bbrc.2014.08.016","volume":"452","author":"M Sedic","year":"2014","unstructured":"Sedic M, Gethings LA, Vissers JP, Shockcor JP, McDonald S, Vasieva O, Lemac M, Langridge JI, Batini\u0107 D, Paveli\u0107 SK (2014) Label-free mass spectrometric profiling of urinary proteins and metabolites from paediatric idiopathic nephrotic syndrome. Biochem Biophys Res Commun 452:21\u201326. https:\/\/doi.org\/10.1016\/j.bbrc.2014.08.016","journal-title":"Biochem Biophys Res Commun"},{"key":"4867_CR96","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ekir.2019.09.010","volume":"5","author":"JR Gooding","year":"2019","unstructured":"Gooding JR, Agrawal S, McRitchie S, Acuff Z, Merchant ML, Klein JB, Smoyer WE, Sumner SJ, Midwest Pediatric Nephrology Consortium (2019) Predicting and defining steroid resistance in pediatric nephrotic syndrome using plasma metabolomics. Kidney Int Rep 5:81\u201393. https:\/\/doi.org\/10.1016\/j.ekir.2019.09.010","journal-title":"Kidney Int Rep"},{"key":"4867_CR97","doi-asserted-by":"publisher","first-page":"316ra193","DOI":"10.1126\/scitranslmed.aac7071","volume":"7","author":"W Ju","year":"2015","unstructured":"Ju W, Nair V, Smith S, Zhu L, Shedden K, Song PXK, Mariani LH, Eichinger FH, Berthier CC, Randolph A, Lai JY, Zhou Y, Hawkins JJ, Bitzer M, Sampson MG, Thier M, Solier C, Duran-Pacheco GC, Duchateau-Nguyen G, Essioux L, Schott B, Formentini I, Magnone MC, Bobadilla M, Cohen CD, Bagnasco SM, Barisoni L, Lv J, Zhang H, Wang HY, Brosius FC, Gadegbeku CA, Kretzler M, ERCB, C-PROBE, NEPTUNE, and PKU-IgAN Consortium (2015) Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med 7:316ra193. https:\/\/doi.org\/10.1126\/scitranslmed.aac7071","journal-title":"Sci Transl Med"},{"key":"4867_CR98","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2337\/db11-1667","volume":"62","author":"JB Hodgin","year":"2013","unstructured":"Hodgin JB, Nair V, Zhang H, Randolph A, Harris RC, Nelson RG, Weil EJ, Cavalcoli JD, Patel JM, Brosius FC 3rd, Kretzler M (2013) Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 62:299\u2013308. https:\/\/doi.org\/10.2337\/db11-1667","journal-title":"Diabetes"},{"key":"4867_CR99","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.kint.2018.05.022","volume":"94","author":"J Tao","year":"2018","unstructured":"Tao J, Mariani L, Eddy S, Maecker H, Kambham N, Mehta K, Hartman J, Wang W, Kretzler M, Lafayette RA (2018) JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis. Kidney Int 94:795\u2013808. https:\/\/doi.org\/10.1016\/j.kint.2018.05.022","journal-title":"Kidney Int"},{"key":"4867_CR100","doi-asserted-by":"publisher","first-page":"e133267","DOI":"10.1172\/jci.insight.133267","volume":"5","author":"R Menon","year":"2020","unstructured":"Menon R, Otto EA, Hoover P, Eddy S, Mariani L, Godfrey B, Berthier CC, Eichinger F, Subramanian L, Harder J, Ju W, Nair V, Larkina M, Naik AS, Luo J, Jain S, Sealfon R, Troyanskaya O, Hacohen N, Hodgin JB, Kretzler M, Kpmp KPMP, Nephrotic Syndrome Study Network (NEPTUNE) (2020) Single cell transcriptomics identifies focal segmental glomerulosclerosis remission endothelial biomarker. JCI Insight 5:e133267. https:\/\/doi.org\/10.1172\/jci.insight.133267","journal-title":"JCI Insight"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04867-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-020-04867-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-020-04867-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T10:08:53Z","timestamp":1629194933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-020-04867-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":100,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["4867"],"URL":"https:\/\/doi.org\/10.1007\/s00467-020-04867-y","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"26 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}